Featured Research

from universities, journals, and other organizations

Two-Drug Combination Therapy Shows Promise Against Melanoma

Date:
June 27, 2000
Source:
University Of California, San Diego School Of Medicine
Summary:
Melanoma researchers at University of California, San Diego (UCSD) have developed a new drug-combination therapy that has proven in Phase II clinical trials to be significantly better at extending patients’ lives than any other drug therapy.

Melanoma researchers at University of California, San Diego (UCSD) have developed a new drug-combination therapy that has proven in Phase II clinical trials to be significantly better at extending patients’ lives than any other drug therapy.

Related Articles


The two drugs, tamoxifen and cisplatin, are commonly used chemotherapeutic agents. Interestingly, neither drug, when used alone, has proven effective against melanoma.

“For reasons that aren’t yet clear, this combination creates a synergism that is highly toxic to melanoma cells,” said Edward F. McClay, M.D., principal investigator of the study and director of the Melanoma Care Unit at UCSD Cancer Center.

Results of the clinical trial are being published in the July 2000 issue of the British Journal of Cancer. The clinical trial was based upon earlier laboratory work in which McClay and colleagues first identified this synergistic interaction.

“If diagnosed and treated early, melanoma is highly curable,” said McClay, professor of medicine at UCSD School of Medicine and a respected national authority on melanoma. “Unfortunately, melanoma is often diagnosed when it’s more advanced and the chances of recurrence are quite high. If it recurs, it often does so with a much more aggressive and lethal personality.”

In this study, the researchers treated 153 patients who were at high risk for recurrence or who had already had a recurrence. Participants received tamoxifen for seven days with the addition of a single dose of cisplatin on the second day; they underwent the weeklong therapy each month for four months. The principal side effect was nausea. With a median follow-up period in this study of 36 months, the researchers can predict with confidence that 79 percent of participants will be alive five years after treatment. Of equal importance, 62 percent of the patients will not have had a tumor recurrence during the five years.

“These statistics, while preliminary, are very encouraging because we have had precious little to offer patients with metastatic melanoma,” said McClay. “With the best currently available treatment, the five-year survival rate in similar patients is only about 35 to 45 percent.”

Because this study was a non-randomized Phase II trial, the researchers stress the importance of next conducting a national multi-site randomized study.

Malignant melanoma is one of the most virulent and deadly types of cancer. This year, at least 48,000 new cases of melanoma will be diagnosed in the United States and 7,700 people will die of the disease. In San Diego there will be approximately 250 new case

This work was supported in part by a grant from the National Cancer Institute and by the Bruce Brunner Gorder Memorial Melanoma Fund. Co-authors are Mary Eileen T. McClay of UCSD Cancer Center; and Linda Monroe, Paul L. Baron, David J. Cole, Paul H. O’Brien, John S. Metcalf and John C. Maize, all of the Hollings Cancer Center of the Medical University of South Carolina, in Charleston, S.C.

The Melanoma Care Unit is a patient-care and research program of UCSD Cancer Center, the only cancer center in San Diego and Imperial counties designated for both research and clinical care by the National Cancer Institute.

For information about melanoma clinical trials at UCSD, call (858) 657-8705; for trials at institutions throughout the U.S., call the National Cancer Institute’s Cancer Information Service at 1-800-4-CANCER.


Story Source:

The above story is based on materials provided by University Of California, San Diego School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, San Diego School Of Medicine. "Two-Drug Combination Therapy Shows Promise Against Melanoma." ScienceDaily. ScienceDaily, 27 June 2000. <www.sciencedaily.com/releases/2000/06/000625233838.htm>.
University Of California, San Diego School Of Medicine. (2000, June 27). Two-Drug Combination Therapy Shows Promise Against Melanoma. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2000/06/000625233838.htm
University Of California, San Diego School Of Medicine. "Two-Drug Combination Therapy Shows Promise Against Melanoma." ScienceDaily. www.sciencedaily.com/releases/2000/06/000625233838.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins